DLA PIPER LLP (US) lobbying for BIOTECHNOLOGY INNOVATION ORGANIZATION

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 17, 2026

Income

$60,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 4

Medical/Disease Research/Clinical Labs

Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. 340B. Orphan drugs. Supply chain. Vaccine policy. Issues related to FDA, drug development, and clinical trial requirements.

Health Issues

Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. 340B. Orphan drugs. Supply chain. Vaccine policy. Issues related to FDA, drug development, and clinical trial requirements.

Medicare/Medicaid

Issues related to reimbursement under Medicare Part B and Part D. Medicare and Medicaid payment and coverage issues. IRA implementation.

Pharmacy

340B drug discount program. General issues related to health care. Issues related to FDA drug review, including PDUFA.